For decades, oncology has been constrained by a fundamental limitation: roughly 80% of disease-driving proteins are structurally unsuited to conventional small-molecule drugs. A rapidly maturing class of bifunctional molecules is systematically dismantling that barrier, with molecular architecture — specifically the chemical bridge connecting two functional ends — emerging as the critical design variable determining therapeutic success.

Proteolysis-targeting chimeras, or PROTACs, work by simultaneously binding a disease-relevant protein and an E3 ubiquitin ligase, forcing the cellular degradation machinery to tag and destroy the pathological target via the ubiquitin-proteasome system. This review in ChemMedChem synthesizes current understanding of how the linker — the molecular tether joining these two binding units — governs degradation efficiency. Key parameters include linker length, which dictates the geometric proximity required for productive ternary complex formation; flexibility versus rigidity, which affects conformational sampling and off-target exposure; and cleavability, which enables tissue-selective or stimulus-responsive payload release. Linker chemistry thus functions less as scaffolding and more as an active pharmacological determinant.

This represents a meaningful consolidation of an accelerating field. PROTACs have already entered clinical trials for androgen receptor-driven prostate cancer and estrogen receptor-positive breast cancer, with ARV-471 (vepdegestrant) generating notable Phase II efficacy data. What this review contributes is a mechanistic framework for interpreting why certain PROTAC candidates succeed where others stall — a historically empirical process now becoming more rational. The central limitation of current PROTAC development remains cell permeability and oral bioavailability, since these molecules are substantially larger than conventional drugs. Linker optimization can partially address both issues. For longevity-focused readers, the broader implication is significant: targeted protein degradation could eventually extend to non-oncology aging proteins, including senescence-associated factors, that have resisted conventional inhibitor strategies. This review is incremental but strategically useful for understanding the engineering logic that will shape next-generation degrader therapeutics.